Contrasting of VistaGen Therapeutics Inc. (VTGN) and Aeterna Zentaris Inc. (NASDAQ:AEZS) – The Broch Herald

VistaGen Therapeutics Inc. (NASDAQ:VTGN) and Aeterna Zentaris Inc. (NASDAQ:AEZS) are two firms in the Biotechnology that compete against each other. Below is a comparison of their risk, analyst recommendations, profitability, dividends, earnings and valuation, institutional ownership.

Earnings & Valuation

Table 1 showcases the gross revenue, earnings per share and valuation of VistaGen Therapeutics Inc. and Aeterna Zentaris Inc.

Profitability

Table 2 demonstrates the net margins, return on assets and return on equity of VistaGen Therapeutics Inc. and Aeterna Zentaris Inc.

Volatility and Risk

VistaGen Therapeutics Inc.s -0.48 beta indicates that its volatility is 148.00% less volatile than that of Standard and Poors 500. Competitively, Aeterna Zentaris Inc.s beta is 1.22 which is 22.00% more volatile than Standard and Poors 500.

Liquidity

VistaGen Therapeutics Inc.s Current Ratio is 4.9 while its Quick Ratio is 4.9. On the competitive side is, Aeterna Zentaris Inc. which has a 2.4 Current Ratio and a 2.3 Quick Ratio. VistaGen Therapeutics Inc. is better positioned to pay off short and long-term obligations compared to Aeterna Zentaris Inc.

Institutional and Insider Ownership

VistaGen Therapeutics Inc. and Aeterna Zentaris Inc. has shares owned by institutional investors as follows: 20.4% and 21.4%. 0.2% are VistaGen Therapeutics Inc.s share owned by insiders. Competitively, insiders own roughly 0.6% of Aeterna Zentaris Inc.s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year VistaGen Therapeutics Inc.s stock price has bigger decline than Aeterna Zentaris Inc.

Summary

VistaGen Therapeutics Inc. beats on 5 of the 9 factors Aeterna Zentaris Inc.

VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for depression and other central nervous system (CNS) disorders. The company's lead product candidate is AV-101, which is in Phase II development stage, an adjunctive treatment used for major depressive disorder. It also focuses on potential commercial applications of its human pluripotent stem cell (hPSC) technology platform to discover, rescue, develop, and commercialize new chemical entities (NCEs) for CNS and other diseases; and regenerative medicine involving hPSC-derived blood, cartilage, heart, and liver cells. In addition, the company develops CardioSafe 3D, an in vitro cardiac bioassay system for predicting human heart toxicity of small molecule NCEs. VistaGen Therapeutics, Inc. has licensing, sublicensing, and collaboration agreements with BlueRock Therapeutics, LP; U.S. National Institutes of Health; Cato Research Ltd.; and University Health Network. The company was founded in 1998 and is headquartered in South San Francisco, California.

Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing novel treatments in oncology, endocrinology, and women's health. The companys product pipeline includes Zoptrex, which completed Phase III clinical study for women with advanced, recurrent, or metastatic endometrial cancer, as well as in various phases for the treatment of ovarian and prostate cancer; and MACRILEN, which completed Phase III trial for use in the diagnosis of adult growth hormone deficiency. It is also developing an LHRH-disorazol Z conjugate, which is in pre-clinical development in oncology. Aeterna Zentaris Inc. was founded in 1991 and is headquartered in Summerville, South Carolina.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Go here to read the rest:
Contrasting of VistaGen Therapeutics Inc. (VTGN) and Aeterna Zentaris Inc. (NASDAQ:AEZS) - The Broch Herald